Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Comcast

LM Ericsson Telefon

JD.com

Nasdaq

PayPal

Roper Technologies

The Nasdaq is known for its high-flying growth stocks, and with good reason. But there's more to the index than just those aggressive names.

The 7 Most Undervalued Nasdaq Stocks to Buy Now: July 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 12th International AIDS Society Conference on HIV Science (IAS 2023), taking place in Brisbane, Australia, and virtually, from July 23-26, 2023. As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs. The breadth of data presented at the m.

Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023

Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.

Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August 3, 2023 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2023 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived th.

Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023

Gilead Sciences Inc. GILD, +0.43% said Friday the U.S. Food and Drug Administration has approved the use of its Veklury, or remdesivir, for patients with severe renal impairment, including those on dialysis. Veklury is now the only approved COVID antiviral for people with all stages of kidney disease.

Gilead Sciences says FDA has approved Veklury in COVID patients with severe kidney disease

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. More than 1 in 7 (37 million) people in the U.

FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis

Allovir, Inc.

Arcus Biosciences

In recent Securities & Exchange Commission filings, Gilead Sciences Inc. NASDAQ: GILD revealed that it had purchased significant stakes in AlloVir Inc. NASDAQ: ALVR and Arcus Biosciences Inc. NYSE: RCUS.

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Analog Devices

Automatic Data Processing

Booking Hlds

Intuitive Surgical

Mondelez

Starbucks

While the market rally this year has been an investor's dream after the nightmare of last year, the reality is that a handful of red-hot technology stocks running higher on the back of the Artificial Intelligence explosion has created almost all of the gains in the S&P 500 and the Nasdaq.

With The Massive NASDAQ Rebalance Coming Soon 7 ‘Strong Buy' Stocks Could Explode Higher

CRISPR Therapeutics

Vertex Pharmaceuticals

Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated assets, meaning their value is sensitive to changes in interest rates.

3 Biotech Stocks to Buy for Long-Term Gains

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF). The second aims to develop investigational pediatric formulations of TAF and sofosbuvir (SOF) designed to eliminate bitterness. For more than 30 years, Gilead has been a leading innovator in the field of HIV, d.

Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries

Agilent Technologies

Autodesk

Amgen

Bank of America

Biogen

Bank of New York Mellon

Blackrock Inc

CME Group

Compass Minerals

Campbell Soup

Copart

Cheniere Energy Partners

Corteva Inc

Disney

Domino's Pizza

Ecolab

Equifax

Estee Lauder

Emerson Electric

Etsy

General Dynamics

Alphabet

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map

Regeneron Pharmaceuticals

Although it's been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at small and midsized biotech companies in the U.S. These are the incubators for medical advancements and where important scientific breakthroughs are happening.

The 3 Best Biotech Stocks to Buy In July

American Electric Power Company

Kraft Heinz

Walgreens

Likely, 2023 will be known as the year artificial intelligence became a permanent part of the investing lexicon.

Why the 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With the Red-Hot Summer Rally

In my last article, I said I liked Nurix, a protein degrader company. Since then, not much has happened at Nurix except Gilead buying into an asset. This is a validation of the company, however, there is no other major development.

Nurix: Still Promising, But No New Development Except Gilead Licensing Asset

Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.

Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion

Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.

Gilead Sciences (GILD) Announces Positive HDV Treatment Data

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Trodelvy® (sacituzumab govitecan) as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the a.

Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® (bulevirtide) for the treatment of adults with chronic hepatitis delta (HDV) infection. These new data presented at the European Association for the Study of the Liver (EASL) Congress 2023 reinforce the role of bulevirtide as an efficacious and well-tolerated treatment for the management.

Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc. This follows the announcement made by Daiichi Sankyo and Kite Pharma, Inc. in December 2022 about changes to their initial 2017 partnersh.

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan

SAN FRANCISCO--(BUSINESS WIRE)--Gilead's Greed Strangles Pharmacies.

AHF: Advocates Slam Gilead over Drug Profiteering

SAN FRANCISCO--(BUSINESS WIRE)--Advocates to Keep Hammering Gilead CEO over Drug Profiteering.

AHF Advocates to Keep Hammering Gilead CEO over Drug Profiteering

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new data to be presented at the European Association for the Study of the Liver (EASL) Congress 2023, June 21-24, 2023. Key findings from more than 70 presentations will include Week 96 data from the pivotal Phase 3 study of Hepcludex® (bulevirtide) evaluating the efficacy and safety for the treatment of hepatitis delta virus (HDV) and late-breaking data on the impact of continued treatment with bulevirtid.

Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023

Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 1:40 PM ET Company Participants Daniel O'Day - Chairman & CEO Merdad Parsey - Chief Medical Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good morning, everyone.

Gilead Sciences, Inc. (GILD) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

The biotech sector remains a fertile place of innovation that can enrich an investor. Gilead has a potential oncology blockbuster, and the stock offers a sizable dividend.

2 Top Biotech Stocks to Buy in June

Pfizer

Peter Lynch is often not considered a dividend investor, which is unfortunate. He has so many valuable insights into dividend stocks that can benefit us. It's just his success with 10-baggers has dominated the spotlights. This article employs Lynch's approach to evaluate Pfizer and Gilead Sciences.

Pfizer Or Gilead Sciences? Let's Ask Peter Lynch

News for Gilead Sciences Stock (GILD)